Skip to main content
Erschienen in: Drugs 5/2014

01.04.2014 | Adis Drug Evaluation

Radium-223 Dichloride: A Review of Its Use in Patients with Castration-Resistant Prostate Cancer with Symptomatic Bone Metastases

verfasst von: Matt Shirley, Paul L. McCormack

Erschienen in: Drugs | Ausgabe 5/2014

Einloggen, um Zugang zu erhalten

Abstract

Radium-223 dichloride (Xofigo®; formerly Alpharadin™) [hereafter referred to as radium-223] is a first-in-class alpha particle-emitting radiopharmaceutical that has recently been approved for the treatment of patients with castration-resistant prostate cancer (CRPC) with symptomatic bone metastases and no known visceral metastatic disease. Radium-223 is a calcium mimetic, which targets bone, delivering cytotoxic radiation to the sites of bone metastases. In the recently reported Alpharadin™ in Symptomatic Prostate Cancer (ALSYMPCA) phase III study, radium-223 was associated with significantly improved overall survival compared with placebo, making it the first bone-targeted CRPC therapy for which an overall survival benefit has been demonstrated. The ALSYMPCA study also demonstrated the beneficial effects of radium-223 on disease-related symptomatic skeletal events, pain and health-related quality of life. Radium-223 was generally well tolerated, being associated with low rates of myelosuppression and generally mild gastrointestinal adverse events. Thus, radium-223 is a valuable addition to the treatment options for this poor-prognosis population.
Literatur
1.
Zurück zum Zitat Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.PubMedCrossRef Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.PubMedCrossRef
2.
Zurück zum Zitat Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract. 2011;65(11):1180–92.PubMedCrossRef Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract. 2011;65(11):1180–92.PubMedCrossRef
3.
Zurück zum Zitat Alva A, Hussain M. The changing natural history of metastatic prostate cancer. Cancer J. 2013;19(1):19–24.PubMedCrossRef Alva A, Hussain M. The changing natural history of metastatic prostate cancer. Cancer J. 2013;19(1):19–24.PubMedCrossRef
4.
Zurück zum Zitat Carles J, Castellano D, Climent MÁ, et al. Castration-resistant metastatic prostate cancer: current status and treatment possibilities. Clin Transl Oncol. 2012;14(3):169–76.PubMedCrossRef Carles J, Castellano D, Climent MÁ, et al. Castration-resistant metastatic prostate cancer: current status and treatment possibilities. Clin Transl Oncol. 2012;14(3):169–76.PubMedCrossRef
5.
Zurück zum Zitat El-Amm J, Aragon-Ching JB. The changing landscape in the treatment of metastatic castration-resistant prostate cancer. Ther Adv Med Oncol. 2013;5(1):25–40.PubMedCentralPubMedCrossRef El-Amm J, Aragon-Ching JB. The changing landscape in the treatment of metastatic castration-resistant prostate cancer. Ther Adv Med Oncol. 2013;5(1):25–40.PubMedCentralPubMedCrossRef
6.
Zurück zum Zitat Mukherji D, Eichholz A, De Bono JS. Management of metastatic castration-resistant prostate cancer: recent advances. Drugs. 2012;72(8):1011–28.PubMedCrossRef Mukherji D, Eichholz A, De Bono JS. Management of metastatic castration-resistant prostate cancer: recent advances. Drugs. 2012;72(8):1011–28.PubMedCrossRef
7.
Zurück zum Zitat Pochon S. Drugs in clinical development for prostate cancer: summary and table. Pharm Med. 2011;25(6):387–404.CrossRef Pochon S. Drugs in clinical development for prostate cancer: summary and table. Pharm Med. 2011;25(6):387–404.CrossRef
8.
Zurück zum Zitat Amaral TMS, Macedo D, Fernandes I, et al. Castration-resistant prostate cancer: mechanisms, targets, and treatment. Prostate Cancer. 2012;2012(327253):1–11.CrossRef Amaral TMS, Macedo D, Fernandes I, et al. Castration-resistant prostate cancer: mechanisms, targets, and treatment. Prostate Cancer. 2012;2012(327253):1–11.CrossRef
9.
Zurück zum Zitat Cookson MS, Roth BJ, Dahm P, et al. Castration-resistant prostate cancer: AUA guideline. J Urol. 2013;190(2):429–38.PubMed Cookson MS, Roth BJ, Dahm P, et al. Castration-resistant prostate cancer: AUA guideline. J Urol. 2013;190(2):429–38.PubMed
10.
Zurück zum Zitat Omlin A, Pezaro C, Mukherji D, et al. Improved survival in a cohort of trial participants with metastatic castration-resistant prostate cancer demonstrates the need for updated prognostic nomograms. Eur Urol. 2013;64(2):300–6.PubMed Omlin A, Pezaro C, Mukherji D, et al. Improved survival in a cohort of trial participants with metastatic castration-resistant prostate cancer demonstrates the need for updated prognostic nomograms. Eur Urol. 2013;64(2):300–6.PubMed
11.
12.
Zurück zum Zitat Lange PH, Vessella RL. Mechanisms, hypotheses and questions regarding prostate cancer micrometastases to bone. Cancer Metastasis Rev. 1999;17(4):331–6.CrossRef Lange PH, Vessella RL. Mechanisms, hypotheses and questions regarding prostate cancer micrometastases to bone. Cancer Metastasis Rev. 1999;17(4):331–6.CrossRef
14.
Zurück zum Zitat Lewington VJ. Bone-seeking radionuclides for therapy. J Nucl Med. 2005;46(1 Suppl):38S–47S.PubMed Lewington VJ. Bone-seeking radionuclides for therapy. J Nucl Med. 2005;46(1 Suppl):38S–47S.PubMed
15.
Zurück zum Zitat Lewis B, Sartor O. Radiation-based approaches for therapy and palliation of advanced prostate cancer. Curr Opin Urol. 2012;22(3):183–9.PubMedCrossRef Lewis B, Sartor O. Radiation-based approaches for therapy and palliation of advanced prostate cancer. Curr Opin Urol. 2012;22(3):183–9.PubMedCrossRef
18.
Zurück zum Zitat Heier-Baardson H, Dornish M. Lack of protective effect by hypoxia on alpha particle radiation from radium-223 [abstract no. 855]. EJC Suppl. 2010;8(5):216.CrossRef Heier-Baardson H, Dornish M. Lack of protective effect by hypoxia on alpha particle radiation from radium-223 [abstract no. 855]. EJC Suppl. 2010;8(5):216.CrossRef
19.
Zurück zum Zitat Henriksen G, Fisher DR, Roeske JC, et al. Targeting of osseous sites with α-emitting 223Ra: comparison with the β-emitter 89Sr in mice. J Nucl Med. 2003;44(2):252–9.PubMed Henriksen G, Fisher DR, Roeske JC, et al. Targeting of osseous sites with α-emitting 223Ra: comparison with the β-emitter 89Sr in mice. J Nucl Med. 2003;44(2):252–9.PubMed
20.
Zurück zum Zitat Nilsson S, Larsen RH, Fosså SD, et al. First clinical experience with α-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res. 2005;11(12):4451–9.PubMedCrossRef Nilsson S, Larsen RH, Fosså SD, et al. First clinical experience with α-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res. 2005;11(12):4451–9.PubMedCrossRef
21.
Zurück zum Zitat Nilsson S, Franzén L, Parker C, et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol. 2007;8(7):587–94.PubMedCrossRef Nilsson S, Franzén L, Parker C, et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol. 2007;8(7):587–94.PubMedCrossRef
22.
Zurück zum Zitat Chittenden S, Hindorf C, Aksnes A, et al. Dosimetry and pharmacokinetics of 223Ra chloride in patients with bone metastases due to hormone refractory prostate cancer [abstract no. P0019]. Eur J Nucl Med Mol Imaging. 2012;39(2 Suppl):S308–9. Chittenden S, Hindorf C, Aksnes A, et al. Dosimetry and pharmacokinetics of 223Ra chloride in patients with bone metastases due to hormone refractory prostate cancer [abstract no. P0019]. Eur J Nucl Med Mol Imaging. 2012;39(2 Suppl):S308–9.
23.
Zurück zum Zitat Lewington V, Parker C, Hindorf C, et al. Radium-223 chloride, a first-in-class alpha-pharmaceutical for patients with castration-resistant prostate cancer (CRPC) and bone metastases: biodistribution/dosimetry compared to overall safety profile [abstract no. e15009]. J Clin Oncol. 2010;28(15 Suppl). Lewington V, Parker C, Hindorf C, et al. Radium-223 chloride, a first-in-class alpha-pharmaceutical for patients with castration-resistant prostate cancer (CRPC) and bone metastases: biodistribution/dosimetry compared to overall safety profile [abstract no. e15009]. J Clin Oncol. 2010;28(15 Suppl).
24.
Zurück zum Zitat Carrasquillo JA, O’Donoghue JA, Pandit-Taskar N, et al. Phase I pharmacokinetic and biodistribution study with escalating doses of 223Ra-dichloride in men with castration-resistant metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2013;40(9):1384–93.PubMedCrossRef Carrasquillo JA, O’Donoghue JA, Pandit-Taskar N, et al. Phase I pharmacokinetic and biodistribution study with escalating doses of 223Ra-dichloride in men with castration-resistant metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2013;40(9):1384–93.PubMedCrossRef
25.
Zurück zum Zitat McDevitt MR, Sgouros G, Finn RD, et al. Radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med. 1998;25(9):1341–51.PubMedCrossRef McDevitt MR, Sgouros G, Finn RD, et al. Radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med. 1998;25(9):1341–51.PubMedCrossRef
26.
Zurück zum Zitat Bruland ØS, Nilsson S, Fisher DR, et al. High-linear energy transfer irradiation targeted to skeletal metastases by the α-emitter 223Ra: adjuvant or alternative to conventional modalities? Clin Cancer Res. 2006;12(20 Suppl):6250s–7s.PubMedCrossRef Bruland ØS, Nilsson S, Fisher DR, et al. High-linear energy transfer irradiation targeted to skeletal metastases by the α-emitter 223Ra: adjuvant or alternative to conventional modalities? Clin Cancer Res. 2006;12(20 Suppl):6250s–7s.PubMedCrossRef
27.
Zurück zum Zitat Franken NAP, Hovingh S, Ten Cate R, et al. Relative biological effectiveness of high linear energy transfer α-particles for the induction of DNA-double-strand breaks, chromosome aberrations and reproductive cell death in SW-1573 lung tumour cells. Oncol Rep. 2012;27(3):769–74.PubMed Franken NAP, Hovingh S, Ten Cate R, et al. Relative biological effectiveness of high linear energy transfer α-particles for the induction of DNA-double-strand breaks, chromosome aberrations and reproductive cell death in SW-1573 lung tumour cells. Oncol Rep. 2012;27(3):769–74.PubMed
29.
Zurück zum Zitat Lassmann M, Nosske D. Dosimetry of 223Ra-chloride: dose to normal organs and tissues. Eur J Nucl Med Mol Imaging. 2013;40(2):207–12.PubMedCrossRef Lassmann M, Nosske D. Dosimetry of 223Ra-chloride: dose to normal organs and tissues. Eur J Nucl Med Mol Imaging. 2013;40(2):207–12.PubMedCrossRef
30.
Zurück zum Zitat Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369(3):213–23.PubMedCrossRef Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369(3):213–23.PubMedCrossRef
31.
Zurück zum Zitat Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649–55.PubMedCrossRef Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649–55.PubMedCrossRef
32.
Zurück zum Zitat Parker C, Heinrich D, O’Sullivan JM, et al. Overall survival benefit of radium-223 chloride (Alpharadin™) in the treatment of patients with symptomatic bone metastases in castration-resistant prostate cancer (CRPC): a phase III randomized trial (ALSYMPCA) [abstract no. 1LBA]. Eur J Cancer. 2011;47(Suppl 2):3.CrossRef Parker C, Heinrich D, O’Sullivan JM, et al. Overall survival benefit of radium-223 chloride (Alpharadin™) in the treatment of patients with symptomatic bone metastases in castration-resistant prostate cancer (CRPC): a phase III randomized trial (ALSYMPCA) [abstract no. 1LBA]. Eur J Cancer. 2011;47(Suppl 2):3.CrossRef
33.
Zurück zum Zitat Vogelzang N, Parker C, Nilsson S, et al. Updated analysis of radium-223 dichloride impact on skeletal-related events (SRE) in patients with castration-resistant prostate cancer (CRPC) and bone metastases from the phase 3 randomized trial (ALSYMPCA) [abstract no. 11 plus poster]. J Clin Oncol. 2013;31(6 Suppl):11. Vogelzang N, Parker C, Nilsson S, et al. Updated analysis of radium-223 dichloride impact on skeletal-related events (SRE) in patients with castration-resistant prostate cancer (CRPC) and bone metastases from the phase 3 randomized trial (ALSYMPCA) [abstract no. 11 plus poster]. J Clin Oncol. 2013;31(6 Suppl):11.
34.
Zurück zum Zitat Parker C, O’Bryan-Tear CG, Bolstad B, et al. Alkaline phosphatase (ALP) normalization and overall survival in patients with bone metastases from castration-resistant prostate cancer (CRPC) treated with radium-223 [abstract no. 49]. J Clin Oncol. 2011;29(7 Suppl):49. Parker C, O’Bryan-Tear CG, Bolstad B, et al. Alkaline phosphatase (ALP) normalization and overall survival in patients with bone metastases from castration-resistant prostate cancer (CRPC) treated with radium-223 [abstract no. 49]. J Clin Oncol. 2011;29(7 Suppl):49.
35.
Zurück zum Zitat Nilsson S, Sartor AO, Bruland OS, et al. Pain analyses from the phase III randomized ALSYMPCA study with radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases [abstract no. 5038]. J Clin Oncol. 2013;31(15 Suppl):5038. Nilsson S, Sartor AO, Bruland OS, et al. Pain analyses from the phase III randomized ALSYMPCA study with radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases [abstract no. 5038]. J Clin Oncol. 2013;31(15 Suppl):5038.
36.
Zurück zum Zitat Tomblyn M, Nilsson S, Vogelzang N, et al. Pain and quality of life (QoL) analyses from the phase 3 randomized ALSYMPCA study with radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases [abstract no. 714]. J Urol. 2013;189(4 Suppl):e293.CrossRef Tomblyn M, Nilsson S, Vogelzang N, et al. Pain and quality of life (QoL) analyses from the phase 3 randomized ALSYMPCA study with radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases [abstract no. 714]. J Urol. 2013;189(4 Suppl):e293.CrossRef
37.
Zurück zum Zitat Esper P, Mo F, Chodak G, et al. Measuring quality of life in men with prostate cancer using the Functional Assessment of Cancer Therapy-Prostate instrument. Urology. 1997;50(6):920–8.PubMedCrossRef Esper P, Mo F, Chodak G, et al. Measuring quality of life in men with prostate cancer using the Functional Assessment of Cancer Therapy-Prostate instrument. Urology. 1997;50(6):920–8.PubMedCrossRef
38.
Zurück zum Zitat Parker CC, Pascoe S, Chodacki A, et al. A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer. Eur Urol. 2013;63(2):189–97.PubMed Parker CC, Pascoe S, Chodacki A, et al. A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer. Eur Urol. 2013;63(2):189–97.PubMed
39.
Zurück zum Zitat Edge SB, Byrd DR, Compton CC, et al., editors. AJCC Cancer Staging Manual. 7th ed. New York: Springer; 2010. Edge SB, Byrd DR, Compton CC, et al., editors. AJCC Cancer Staging Manual. 7th ed. New York: Springer; 2010.
41.
Zurück zum Zitat Harrison MR, Wong TZ, Armstrong AJ, et al. Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease. Cancer Manag Res. 2013;5(1):1–14.PubMedCentralPubMedCrossRef Harrison MR, Wong TZ, Armstrong AJ, et al. Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease. Cancer Manag Res. 2013;5(1):1–14.PubMedCentralPubMedCrossRef
42.
Zurück zum Zitat Bayer. A re-treatment safety study of radium-223 dichloride in subjects with castration-resistant prostate cancer with bone metastases who received an initial course of six doses of radium-223 dichloride 50 kBq/kg every four weeks [ClinicalTrials.gov identifier: NCT01934790]. US National Institutes of Health, ClinicalTrials.gov (online). 2014. http://clinicaltrials.gov/ct2/show/NCT01934790?term=NCT01934790&rank=1. Accessed 24 Feb 2014. Bayer. A re-treatment safety study of radium-223 dichloride in subjects with castration-resistant prostate cancer with bone metastases who received an initial course of six doses of radium-223 dichloride 50 kBq/kg every four weeks [ClinicalTrials.gov identifier: NCT01934790]. US National Institutes of Health, ClinicalTrials.gov (online). 2014. http://​clinicaltrials.​gov/​ct2/​show/​NCT01934790?​term=​NCT01934790&​rank=​1. Accessed 24 Feb 2014.
Metadaten
Titel
Radium-223 Dichloride: A Review of Its Use in Patients with Castration-Resistant Prostate Cancer with Symptomatic Bone Metastases
verfasst von
Matt Shirley
Paul L. McCormack
Publikationsdatum
01.04.2014
Verlag
Springer International Publishing
Erschienen in
Drugs / Ausgabe 5/2014
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-014-0198-4

Weitere Artikel der Ausgabe 5/2014

Drugs 5/2014 Zur Ausgabe